Accredited Investors Employee Shareholders Institutions Private Companies Who We Serve Trading and InvestingData SolutionsPrivate Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage toolBrowse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunitiesForge DataAnalyze private markets via Forge’s intuitive web applicationForge Private Market IndexMonitor a benchmark for actively traded private companies Forge Accuidity Private Market IndexInvest in an institutionally-managed diversified basket of private companies (QPs only)Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All InsightsPrivate Market ReportsMarket InsightsBuying and Selling Pre-IPO All ReportsPrivate Market Updates Forge Investment OutlookStartup News and TrendsPrivate Market Data and AnalyticsTech IPO Calendar for 2024Private Market ExplainedBuying Pre-IPO SharesSelling Pre-IPO Shares Glossary Videos FAQsInsights About Us Leadership Investor Relations People & Culture Careers About

Aktis Oncology Stock

Q: How to sell Aktis Oncology stock?

If you hold private company shares of Aktis Oncology - whether as an employee or an early investor - Forge can help you sell them. 1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have. 2. Indicate your interest to sell your Aktis Oncology stock on our platform. 3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

aktisoncology.comHealthcare / BioTech & PharmaFounded: 2019

Aktis Oncology is a biopharma solutions company that specializes in cancer care with novel platform technologies. Aktis Oncology uses powerful, radiopharmaceuticals to target therapies that harness alpha-emitting participles designed to optimize treatment options.

Buy or sell Aktis Oncology stockLearn more about Aktis Oncology IPO

OverviewFinancingsValuation

Enterprise Value

Access Aktis Oncology’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Aktis Oncology.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Aktis Oncology investors also invested in these private companies

Bristol Myers Squibb

Attralus, Capstan Therapeutics, Zenas BioPharma, BigHat Biosciences, Vedanta Biosciences, Cour Pharmaceuticals Development, Aktis Oncology, Accent Therapeutics, Cellares, Obsidian Therapeutics

MPM Capital

Orna Therapeutics, Aktis Oncology, Photys Therapeutics

Octagon Capital Advisors

Aktis Oncology, Hummingbird Bioscience, Cullgen, Bluejay Therapeutics

VIDA Ventures

Capstan Therapeutics, Quanta Therapeutics, Scorpion Therapeutics, Aktis Oncology, Alterome Therapeutics

Novartis

Capstan Therapeutics, Orionis Biosciences, Aktis Oncology, Alto Neuroscience, Flare Therapeutics, Binx Health

TCG

ADARx Pharmaceuticals, Aktis Oncology, RayzeBio, Obsidian Therapeutics, Arbor Biotechnologies

Team

Management Team

Matthew Roden, PhD

President & Chief Executive Officer

Paul L. Feldman, PhD

Chief Scientific Officer

Pankaj Bhargava, MD

Interim Chief Medical Officer

Brian Goodman, PhD

Co-Founder & Chief Operating Officer

Ved Srivastava, PhD

Vice President, Head of Chemistry

Karen McCarthy

Executive Director, Head of Finance

Tyler Benedum, PhD

Senior Vice President, Head of Chemistry, Manufacturing, and Controls

Dasa Lipovsek, PhD

Vice President, Head of Lead Discovery

Kelly Polanco

Vice President, Head of People & Culture

Carlos Rodriguez

Executive Director, Corporate Development

Lorraine Horgan

Executive Director, Head of Program Management

Janet Horton, MD

Executive Director, Clinical Development

Board Members

Todd Foley

MPM Capital

Helen Kim, MBA

Vida Ventures

Oleg Nodelman

EcoR1 Capital

Lloyd M. Segal, MBA

Repare Therapeutics

Aktis Oncology stock FAQs

Can you buy Aktis Oncology stock?

As Aktis Oncology is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like Aktis Oncology, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.

How to buy Aktis Oncology stock?

To invest in a private company like Aktis Oncology through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Aktis Oncology stock?

Yes, you may be able to sell your Aktis Oncology stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Aktis Oncology stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Aktis Oncology stock on our platform.
Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.

Is Aktis Oncology a public company?

No, Aktis Oncology is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Aktis Oncology’s stock price?

Aktis Oncology is a privately held company and therefore does not have a public stock price. However, you may access Aktis Oncology’s private market stock price with Forge Data.

What is Aktis Oncology’s stock ticker symbol?

Aktis Oncology does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Crunchbase 09/06/2022

Aktis Oncology Nabs A Rare Upround of $84M In Extension Funding

Biotech firm Aktis Oncology announced Thursday it closed an $84 million extension round partially funded by large pharma companies like Merck, Bristol Myers Squibb and Novartis.

Browse More Insights

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.